NAMPT
Nicotinamide phosphoribosyltransferase (NAMPT; EC 2.4.2.12), was originally discovered as the cytokine pre-B-cell colony-enhancing factor 1 (PBEF1) or visfatin, and has several suggested functions. It was found to be an important cofactor for stem cell factor– and interleukin (IL)-7-mediated B cell maturation. However, in 2002 the murine homologue of PBEF was found, and this proved to be an enzyme catalyzing the reaction between nicotinamide and 5-phosphoribosyl-1-pyrophosphate yielding nicotinamide mononucleotide (NMN), an intermediate in the biosynthesis of NAD/NADH: central molecules involved in energy metabolism, reductive biosynthesis, and antioxidation, histone deacetylation, cell death, and intracellular calcium release. This widened its potential biological activities. Interestingly, both extracellular (cytokine-like) and intracellular (enzymatic) functions seem to be responsible for its relevance in immunity, metabolism, and stress responses in both physiology and pathophysiology[1].
[1] T.B. Dahl, S. Holm , P. Aukrust, B. Halvorsen. Visfatin/NAMPT: a multifaceted molecule with diverse roles in physiology and pathophysiology. Annu. Rev. Nutr. 2012, 32, 229-243.
Axon ID | Name | Description | From price | |
---|---|---|---|---|
1279 | FK 866 | NAMPT inhibitor; NAD biosysthesis inhibitor | €90.00 | |
1546 | FK 866 hydrochloride | NAMPT inhibitor | €90.00 | |
3557 | KPT-9274 | Orally bioavailable dual PAK4/NAMPT inhibitor | €130.00 | |
2602 | P7C3 | Proneurogenic and neuroprotective compound that activates NAMPT | €105.00 | |
3954 | SBI-797812 | Orally active NAMPT activator | €130.00 | |
2253 | STF 118804 | Highly specific, next-generation NAMPT inhibitor | €120.00 |